NRG5051 is a first-in-class, orally bioavailable and CNS-penetrant next-generation inhibitor of the mitochondrial permeability transition pore (mPTP), acting through a novel undisclosed ...
The first healthy volunteers have been dosed in an early clinical trial testing NRG5051, a disease-modifying therapy for ALS ...
New U.S. intellectual property protections expand use of Minovia’s leading technology in mitochondrial-based therapies for primary mitochondrial and severe renal diseasesHAIFA, Israel, Jan. 13, 2026 ...
Pretzel Therapeutics is advancing its mitochondrial disease therapies, pushing lead candidate PX578 through Phase 1 trials ...
A study led by Shoukhrat Mitalipov, Ph.D., and Hong Ma, M.D., Ph.D., at the Center for Embryonic Cell and Gene Therapy at Oregon Health & Science University and the Oregon National Primate Research ...
Reduction in mitochondrial activity in multiple sclerosis contributes to Purkinje cell loss. Researchers at the University of California, Riverside (CA, USA) have demonstrated the role mitochondrial ...
The UK’s pioneering licensed IVF technique to reduce the risk of mitochondrial diseases carried out in Newcastle has seen eight babies born, published research shows. All eight babies show no signs of ...
Children born to women who carry pathogenic variants in mitochondrial DNA (mtDNA) are at risk for a range of clinical syndromes collectively known as mtDNA disease. Mitochondrial donation by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback